| ID | 1018 |
| Name of the vaccine | DT Generic |
| Microbe | Bacteria |
| Disease name | Diphtheria |
| Name of bacteria | Corynebacterium diphtheriae |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 6 weeks to 6 years |
| Description of the vaccine | Diphtheria and tetanus toxoids adsorbed (DT vaccine). Use when pertussis is contraindicated. |
| Name of the manufacturer | Sanofi Pasteur Limited |
| Name of the manufacturing country | Canada |
| Year of manufacture | 1997 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Five doses at 2, 4, 6, 15-18 months and between 4 and 6 years. |
| Mechanism of action | Serum diphtheria antitoxin level of at least 0.1 IU/mL is protective. |
| Route of administration | Intramuscular |
| Indications | Active immunization against diphtheria and tetanus. |
| Export | Distributed by Sanofi Pasteur Inc, USA |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | For tetanus also. |
| Side effects of vaccine | Crying, fever, and loss of appetite. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/119411/download |
| Other name | NA |
| Additional Links | NA
|